New York State Common Retirement Fund Sells 107,008 Shares of Enfusion, Inc. (NYSE:ENFN)

New York State Common Retirement Fund cut its holdings in Enfusion, Inc. (NYSE:ENFN - Free Report) by 6.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,556,470 shares of the company's stock after selling 107,008 shares during the quarter. New York State Common Retirement Fund owned approximately 1.21% of Enfusion worth $14,771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enfusion in the 1st quarter worth about $44,000. RiverPark Advisors LLC purchased a new stake in Enfusion in the second quarter worth about $68,000. Arizona State Retirement System bought a new stake in Enfusion during the 2nd quarter valued at approximately $86,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Enfusion during the 1st quarter worth approximately $102,000. Finally, Quadrature Capital Ltd bought a new position in shares of Enfusion in the 1st quarter worth approximately $109,000. Hedge funds and other institutional investors own 81.05% of the company's stock.

Enfusion Stock Performance

Shares of NYSE ENFN traded up $0.37 during mid-day trading on Wednesday, hitting $9.32. 897,138 shares of the stock traded hands, compared to its average volume of 371,983. The stock has a fifty day moving average price of $8.77 and a 200-day moving average price of $8.84. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 223.81, a PEG ratio of 2.51 and a beta of 0.93. Enfusion, Inc. has a 52 week low of $7.52 and a 52 week high of $10.45.

Enfusion (NYSE:ENFN - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Enfusion had a return on equity of 6.17% and a net margin of 1.98%. The business had revenue of $49.46 million during the quarter, compared to analysts' expectations of $50.27 million. As a group, sell-side analysts predict that Enfusion, Inc. will post 0.07 EPS for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.